Matrix metalloproteinas-9 functional promoter polymorphism 1562C>T increased risk of early-onset coronary artery disease

[1]  Mozafari Hadi,et al.  The frequency of factor V Leiden mutation, ACE gene polymorphism, serum ACE activity and response to ACE inhibitor and angiotensin II receptor antagonist drugs in Iranians type II diabetic patients with microalbuminuria , 2011 .

[2]  Z. Rahimi,et al.  Plasma lipids and lipoproteins in children and young adults with major β-thalassemia from western Iran: influence of genotype , 2011, Molecular Biology Reports.

[3]  Z. Rahimi,et al.  The frequency of factor V Leiden mutation, ACE gene polymorphism, serum ACE activity and response to ACE inhibitor and angiotensin II receptor antagonist drugs in Iranians type II diabetic patients with microalbuminuria , 2011, Molecular Biology Reports.

[4]  Kurt Hulyam,et al.  Is a single nucleotide polymorphism a risk factor for lung cancer in the matrix metalloproteinase-2 promoter? , 2011, Molecular Biology Reports.

[5]  Z. Rahimi,et al.  Association between apolipoprotein ε4 allele, factor V Leiden, and plasma lipid and lipoprotein levels with sickle cell disease in southern Iran , 2011, Molecular Biology Reports.

[6]  Hao Xu,et al.  Toll-like receptors 4 induces expression of matrix metalloproteinase-9 in human aortic smooth muscle cells , 2011, Molecular Biology Reports.

[7]  Z. Rahimi,et al.  Butyrylcholinesterase K variant and the APOE-ε4 allele work in synergy to increase the risk of coronary artery disease especially in diabetic patients , 2010, Molecular Biology Reports.

[8]  L. Gu,et al.  Apolipoprotein E polymorphism in normal Han Chinese population: frequency and effect on lipid parameters , 2009, Molecular Biology Reports.

[9]  Z. Rahimi,et al.  Serum butyrylcholinesterase activity and phenotype associations with lipid profile in stroke patients. , 2009, Clinical biochemistry.

[10]  R. Mehta,et al.  Pre-operative homocysteine levels and morbidity and mortality following cardiac surgery , 2008, European heart journal.

[11]  O. Wiklund,et al.  Release of protein as well as activity of MMP‐9 from unstable atherosclerotic plaques during percutaneous coronary intervention , 2007, Journal of internal medicine.

[12]  Z. Rahimi,et al.  The presence of apolipoprotein ε4 and ε2 alleles augments the risk of coronary artery disease in type 2 diabetic patients , 2007 .

[13]  Leong L Ng,et al.  Plasma matrix metalloproteinase-9 and left ventricular remodelling after acute myocardial infarction in man: a prospective cohort study. , 2007, European heart journal.

[14]  A. Branzi,et al.  Matrix metalloproteinases in premature coronary atherosclerosis: influence of inhibitors, inflammation, and genetic polymorphisms. , 2007, Translational research : the journal of laboratory and clinical medicine.

[15]  H. Markus,et al.  The role of genetic variants of matrix metalloproteinases in coronary and carotid atherosclerosis , 2006, Journal of Medical Genetics.

[16]  H. Kharrazi,et al.  Association between apolipoprotein E polymorphism and coronary artery disease in the Kermanshah population in Iran. , 2006, Clinical biochemistry.

[17]  Bronwyn A. Kingwell,et al.  Matrix Metalloproteinase-9 Genotype Influences Large Artery Stiffness Through Effects on Aortic Gene and Protein Expression , 2004, Arteriosclerosis, thrombosis, and vascular biology.

[18]  Johan Sundström,et al.  Relations of Plasma Matrix Metalloproteinase-9 to Clinical Cardiovascular Risk Factors and Echocardiographic Left Ventricular Measures: The Framingham Heart Study , 2004, Circulation.

[19]  A. Morgan,et al.  Haplotypic analysis of the MMP-9 gene in relation to coronary artery disease , 2003, Journal of Molecular Medicine.

[20]  F. Cambien,et al.  Plasma Concentrations and Genetic Variation of Matrix Metalloproteinase 9 and Prognosis of Patients With Cardiovascular Disease , 2003, Circulation.

[21]  A. Cho,et al.  Matrix Metalloproteinase-9 Is Necessary for the Regulation of Smooth Muscle Cell Replication and Migration After Arterial Injury , 2002, Circulation research.

[22]  P. Manow.  ‚The Good, the Bad, and the Ugly‘ , 2002 .

[23]  R. Romero,et al.  A polymorphism in the matrix metalloproteinase-9 promoter is associated with increased risk of preterm premature rupture of membranes in African Americans. , 2002, Molecular human reproduction.

[24]  Z. Galis,et al.  This Review Is Part of a Thematic Series on Matrix Metalloproteinases, Which Includes the following Articles: Matrix Metalloproteinase Inhibition after Myocardial Infarction: a New Approach to Prevent Heart Failure? Matrix Metalloproteinases in Vascular Remodeling and Atherogenesis: the Good, the Ba , 2022 .

[25]  T. Lehtimäki,et al.  Coronary Artery Complicated Lesion Area Is Related to Functional Polymorphism of Matrix Metalloproteinase 9 Gene: An Autopsy Study , 2001, Arteriosclerosis, thrombosis, and vascular biology.

[26]  J. D’Armiento,et al.  Disruption of the myocardial extracellular matrix leads to cardiac dysfunction. , 2000, The Journal of clinical investigation.

[27]  A. Henney,et al.  Genetic variation at the matrix metalloproteinase-9 locus on chromosome 20q12.2–13.1 , 1999, Human Genetics.

[28]  A. Evans,et al.  Functional polymorphism in the regulatory region of gelatinase B gene in relation to severity of coronary atherosclerosis. , 1999, Circulation.

[29]  T. Ueno,et al.  Peripheral blood levels of matrix metalloproteases-2 and -9 are elevated in patients with acute coronary syndromes. , 1998, Journal of the American College of Cardiology.

[30]  G. Gibbons,et al.  The emerging concept of vascular remodeling. , 1994, The New England journal of medicine.

[31]  W. Stetler-Stevenson,et al.  Quantitative zymography: detection of picogram quantities of gelatinases. , 1994, Analytical biochemistry.

[32]  J. Ubbink,et al.  Rapid high-performance liquid chromatographic assay for total homocysteine levels in human serum. , 1991, Journal of chromatography.

[33]  K. Cherian,et al.  Genetic variants on apolipoprotein gene cluster influence triglycerides with a risk of coronary artery disease among Indians , 2009, Molecular Biology Reports.

[34]  K. Zen,et al.  Functional polymorphisms of matrix metallopeptidase-9 and risk of coronary artery disease in a Chinese population , 2009, Molecular Biology Reports.

[35]  R. Zhou,et al.  Association of functional polymorphisms in MMPs genes with gastric cardia adenocarcinoma and esophageal squamous cell carcinoma in high incidence region of North China , 2009, Molecular Biology Reports.

[36]  Z. Rahimi,et al.  Butyrylcholinesterase K variants increase the risk of coronary artery disease in the population of western Iran. , 2008, Scandinavian journal of clinical and laboratory investigation.

[37]  R. Bernat,et al.  C-reactive protein gene polymorphisms affect plasma CRP and homocysteine concentrations in subjects with and without angiographically confirmed coronary artery disease , 2008, Molecular Biology Reports.

[38]  A. Naylor,et al.  Increased matrix metalloproteinase-9 activity in unstable carotid plaques. A potential role in acute plaque disruption. , 2000, Stroke.